Zimba 1% Cream contains Ozenoxacin 1% w/w, a topical non-fluorinated quinolone antibiotic indicated for the treatment of impetigo and other superficial bacterial skin infections caused by susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. Ozenoxacin exhibits bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair. The cream formulation allows for targeted delivery to the site of infection, minimizing systemic absorption and reducing the risk of systemic side effects. Zimba 1% Cream is applied topically to the affected area twice daily, typically for a duration of 5 days, or as directed by a healthcare professional. It is well tolerated with a low incidence of local adverse reactions such as mild erythema or pruritus. Caution is advised in patients with known hypersensitivity to quinolone antibiotics. Use during pregnancy and lactation should be considered only if the potential benefit justifies the potential risk to the fetus or infant. Zimba 1% Cream offers an effective therapeutic option for managing superficial bacterial skin infections, promoting rapid resolution of lesions and reducing the risk of bacterial resistance development through its potent antimicrobial activity.